Nicolas Moosmann
Ludwig Maximilian University of Munich
35 Papers
185 Citations
Nicolas Moosmann is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Cetuximab & Irinotecan. The author has an hindex of 13, co-authored 27 publications.
Chat about Author
Papers
Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer
Stefan Boeck,Ralf Wilkowski,Christiane Bruns,Rolf-Dieter Issels,Christoph Schulz,Nicolas Moosmann,D. Laessig,Michael Haas,Alexander Golf,Volker Heinemann +9 more
TL;DR: Oral capecitabine (Cap) was offered to patients who had already received at least 1 previous treatment regimen containing full-dose Gem and was found to be a safe treatment option for Gem-pretreated patients with advanced pancreatic cancer.
A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition.
TL;DR: This work presents a scoring tool for acneiform skin eruptions, which is calculated from body involvement, facial involvement and clinical grading of the skin items erythema, papulation, pustulation and scaling/crusts, and gives a number between 0 and 100.
47
Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.
Beate Rau,Hauke Lang,Alfred Koenigsrainer,Ines Gockel,Horst-Guenter Rau,Hendrik Seeliger,Christian Lerchenmueller,Daniel Reim,Roger Wahba,Martin Angele,Steffen Heeg,Tobias Keck,Arved Weimann,Stefan Topp,Pompiliu Piso,A. Brandl,Silke Schuele,Peter Jo,J. Pratschke,Sandra Wegel,A. Rehders,Nicolas Moosmann,Jochen Gaedcke,Volker Heinemann,Evelyn Trips,Markus Loeffler,P. Schlag,P. Thuss-Patience +27 more
TL;DR: This study showed no OS difference between CRS + H and CRS-A, which needs further exploration, and PFS and MFS were significantly better in the CRS + H group, which needs further exploration.
42
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Sebastian Stintzing,L. Fischer von Weikersthal,Ursula Vehling-Kaiser,Martina Stauch,Holger G. Hass,H. Dietzfelbinger,Daniel Oruzio,S. Klein,Klaus Zellmann,Thomas Decker,M. Schulze,W. Abenhardt,Gerhard Puchtler,Herbert W. Kappauf,Johann Mittermüller,Christopher Haberl,Clemens Giessen,Nicolas Moosmann,Volker Heinemann +18 more
TL;DR: This analysis supports the hypothesis that for the evaluated regimens, a correlation exists between capecitabine-attributed ST and treatment efficacy regarding DCR, PFS, and OS.
27
Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group
Volker Heinemann,L. Fischer von Weikersthal,Ursula Vehling-Kaiser,Martina Stauch,Daniel Oruzio,M. Schulze,Holger G. Hass,J. Weiss,H. Dietzfelbinger,Nicolas Moosmann +9 more
TL;DR: This randomized trial compared the first and second doses of cetuximab combined with 5-fluorouracil/folinic acid plus irinotecan or oxaliplatin in the treatment of mCRC.
18